ASSOCIATION OF VITAMIN D STATUS WITH CARCINOMA ESOPHAGUS AND ITS OUTCOME
Main Article Content
Keywords
carcinoma, esophagus, chemotherapy
Abstract
INTRODUCTION:In India esophageal carcinoma is most common malignancy involving gastrointestinal tract in Karnataka, Kerala, Tamil Nadu and Assam. In Kashmir esophageal carcinoma is ranking at number one, but there is scarcity of epidemiological studies in this regard AIM:To study vitamin D level in patients with carcinoma esophagus.
METHODOLOGY:All patients who were registered at Regional cancer centre, as a case of carcinoma esophagus were enrolled in the study. This was a prospective case control study. Study group was divided into two groups-case and control group.
- Cases included patients with histological confirmation of carcinoma esophagus. (Group A)
- Control group included healthy member from the family. (Group B)
Blood samples were taken from the patients and control group and vitamin D levels were calculated by ELISA method.
- Inclusion criteria
- All patients with histological confirmation of carcinoma esophagus were included in the study.
- Exclusion criteria
- Patients who had co-morbid conditions .
- Patients who had undergone surgery.
Data Analysis: Data was analysed using SPSS software version 20.
OBSERVATIONS : In this case control study 165 cases and 142 controls participated. The mean age of cases and controls was 60.74±74 and 54.78±9.29 years respectively.52.7 % cases were smokers as against controls 33.1% and the difference was statistically significant (p<0.05).Majority of the patients (86.1%) had grade I dysphagia at presentation. 47.88% had well differentiated carcinoma. Vitamin D estimation showed that among cases 58.2% were deficient compared to controls where levels were 66.2.This difference was statistically significant.
CONCLUSION: It seems vitamin D deficiency does not play significant role in development of esophageal cancer. However, when vitamin D supplement was given to deficient/ insufficient patients prior to specific treatment we found that they did better in terms of improvement in dysphagia, loco-regional control and response.
References
2. Parkin PM, Bray FI, Dersa SS. cancer burden in the year 2000. Global picture eur j cancer 2001.
3. Sundel of M, Ye W. Dicman PW, Langergren J. Improved survival in both histological types of esophageal cancer in Sweden. Int. J cancer 2002;99 751-54.
4.Khan N.A et al; A survey of risk factor in carcinoma esophagus in Kashmir valley”, journal of cancer research and therapeutics 2011, vol 7 (1) 15-18.
5.Hishicawa Y, Kurisi K, Tangiguishi M , Kamikanya N, miura T- dose intra luminal Brachytherepy for esopheageal cancer. Int. J radiation oncology Biol phys ( 1991) 21;1133-35.
6.Tavani A, Bertuzi M etal. Coffee and tea drinking and risk of oral, pharyngeal cancer. Int J cancer 2003;107:283-84.
7.Langergren J, Bergstron R, Hindgren, Nyron O; ‘’ symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma” N, Engl.J.M 1999,340 (11). 825-31.
8.Syrjanenky. HPV infection and esophageal cancer. J. Clin. Pathol 2002,55(10); 721-800.
9.Green PH , Fleichaue AT , Bhagat G , Goyal R, Jabri B , Neugut AL .’’ risk of malignancy in patients with celiac disease.’’. AMJ Med. 115(3)2000;191-94.
10.Merry AH, Schouten L J, Goldbohm R A and Vanden Bradnt PA. Body mass index, height and risk of adenocarcinoma and gastric cardia: a prospective cohart study.’ Gut 56 (11) 2007:1503/gut 2006.
11.Park w, Vaezi M. Etiology and Pathogenesis of Achalasia: The current understanding. American journal of gastroenterology 2005,100 (6): 1404-1414.
12.Gourav K , Rath , Bidhu k Kohanti, cancer of esophagus. Text book of radiation oncology (407-412).
13.Lipworth L, Rossi M,Mclaughlim J.K, Negri.E, Talamin.R, Levi.F, Franceschi.S & Vecchia La.c; Dietary vit. D & cancers of oral cavity & oesophagus;Annals of oncology 2009,vol.20,p.1576-1581.
14.Corky DAK erlikowske k, Verma R, Buffler P. Protect association of aspirin /NSIADS and esophageal cancer: a systematic review and meta analysis. Gastroenterology 2003:124;47-56.
15.NCI prevention:dietary factors , based on Chainani –wee. N Diet and oral, pharyngeal and esophageal cancer. Nutra cancer 2002,44: 104-126.
16.Nakajimas S,Hattori.T.”Esophageal adenocarcinoma or gasrric cancer with or without eradication of H.pylori infection in chronic atrophic gastritis patients:a hypothetical opinion from systemic review”Aliment .pharmacol.ther.2004,20 suppl 1:54,dio 10.11I/J.
17.Wilkins WE, Walkers J, McNulty MR. The organisation and evaluation of an open access dysphagia clinic. Ann R Coll surg engl 1984; 66:115-16.
18.Rosen N. The molecular bases for cellular transformation implication for esophageal carcinogenesis. Sem. Oncol. (1994) pp; 416-424.
20.Brewster AE, Davidson SE, Makin wp etal, intraluminal brachytherapy using high dose microselection in palliation of carcinoma esophagus clin. Onco 1995;7:102-5..
21.Fleet JC, DeSmet M, Johnson R, et al. Vitamin D and cancer: a review of molecular mechanisms. Biochem J 2012;441:61-76.
22.Lips P. Vitamin D physiology. Prog Biophys Mol Biol 2006;92:4-8.
21.Zou XN , Taylor PR, Mark SD, et al Seasonal variation of food consumption and selected nutrient intake in linxian, a high risk area for esophgeal cancer in China . Int of J ,Vitam, nutria, resources 2002,vol 72, P-375-382
22.Carlos; A. Peraz, Luther w Brady. Principles and practices of radiation oncology. chap. 36,page 700.
23.Bosetti C, Levi F, Ferlay J, Garavello W, Lucchini F, Bertuccio P, Negri E, La Vecchia C. Trends in oesophageal cancer incidence and mortality in Europe. Int J Cancer. 2008 Mar 1;122:1118-29. doi: 10.1002/ijc.23232.
24.Maria Aparecida Coelho de Arruda HenryI, Mauro Masson LercoII, Priscila Watson RibeiroIII, Maria Aparecida Marchesan RodriguesIV Epidemiological features of esophageal cancer. Squamous cell carcinoma versus adenocarcinoma. Acta Cirúrgica Brasileira - Vol. 29 (1) 2014 – 877
25.Nazir A. Dar,1,2,7 Idrees A. Shah,1 Gulzar A. Bhat,1 Muzamil A. Makhdoomi,1 Beenish Iqbal,1 Rumaisa Rafiq,1 Iqra Nisar,1 Arshid B. Bhat,1 Sumaiya Nabi,1 Akbar Masood,1 Sajad A. Shah,1 Mohd M. Lone,3 Showkat A. Zargar,4 Farhad Islami2,5 and Paolo Boffetta2,6,7 Socioeconomic status and esophageal squamous cell carcinoma risk in Kashmir, India. Cancer Sci | September 2013 | vol. 104 | no. 9 | 1235
26.Dietz J, Pardo SH, Furtado CD, Harzheim, Furtado AD. Fatores de risco relacionados ao câncer de esôfago no Rio Grande do Sul. Rev Assoc Med Bras. 1998 Oct-Dec;44(4):269-72. doi: org/10.1590/ S0104-42301998000400003.
27.Akhtar, S (February 2013). "Areca nut chewing and esophageal squamous-cell carcinoma risk in Asians: a meta-analysis of case-control studies". Cancer Causes & Control 24(2): 257–65. February 2013, Volume 24, Issue 2, pp 257-265.
28.Baquet CR, Commiskey P, Mack K, Meltzer S, Mishra SIEsophageal cancer epidemiology in blacks and whites: racial & gender disparities in incidence, mortality, survival rates and histology.J Natl Med Assoc. 2005 Nov;97(11):1471-8.
29.Carstensen JM, Pershagen G, Eklund G. Mortality in relation to cigarette and pipe smoking: 16 years’ observation of 25,000 Swedish men. J Epidemiol Community Health 1987; 41: 166–72.
30.Cook-Mozaffari PJ, Azordegan F, Day NE, Ressicaud A, Sabai C, Aramesh B. Oesophageal cancer studies in the Caspian Littoral of Iran: results of a case-control study. Br J Cancer 1979; 39: 293–309.
31.Freedman ND, Abnet CC, Leitzmann MF et al. A prospective study of tobacco, alcohol, and the risk of esophageal and gastric cancer subtypes. Am J Epidemiol 2007; 165: 1424–33.
32.Yen-Hao Chen1,2, Hung-I. Lu3, Chih-Yen Chien4, Chien-Ming Lo3, Yu-Ming Wang5, Shang-Yu Chou5, Yan-Ye Su4, Li-Hsueh Shih6 & Shau-Hsuan Li. Treatment Outcomes of Patients with Locally Advanced Synchronous Esophageal and Head/Neck Squamous Cell Carcinoma Receiving Curative Concurrent Chemoradiotherapy. Sci. Rep. 7, 41785; doi: 10.1038/srep41785 (2017).
33.Gupta V, Bhardwaj S, Bhagat OK. Pattern of esophageal cancer in tertiary care hospital in North India: a clinicopathological study. Int J Res Med Sci 2017;5:1405-9.
34.Muro K, Ohtsu A, Ishikura S, et al: A phase II study of chemoradiotherapy in patients with stage II, III esophageal squamous cell carcinoma (ESCC): (JCOG 9906). J Clin Oncol 25 (suppl):644s, 2007 (abstr 15137)
35.Airoldi M, Cortesina G, Giordano C, et al: Docetaxel and vinorelbine: an effective regimen in recurrent squamous cell esophageal carcinoma. Med Oncol 20:19–24, 2003.
36.Grant WB (2002) An estimate of premature cancer mortality in the US due to inadequate doses of solar ultraviolet-B radiation. Cancer 94: 1867– 1875
37. Dancey J, Zee B, Osoba D, et al: Quality of life scores: an inde¬pendent prognostic variable in a general population of cancer patients receiving chemotherapy. The National Cancer Institute of Canada Clinical Trials Group. Qual Life Res 6: 151 158, 1997.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.
Dr.Shabir Ahmad Dar
Dr.Zaffar Iqbal Kawoosa ,Associate Professor Medicine Govt Medical College, Baramulla
Dr.Shah Syed Mahmood Kadri
Specialist General and Trauma Surgery, Sheikh Khalifa Medical City Ajman
Dr.Touseef Ahmad Mir
Medical Officer, J& K Health Services
Dr.Zaffar Iqbal Kawoosa
Associate Professor Medicine Govt Medical College, Baramulla(corresponding author)
Dr.Sajad
Faculty SKIMS MCH